Dynavax Technologies (NASDAQ:DVAX) Share Price Passes Above 200-Day Moving Average – What’s Next?

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.19 and traded as high as $15.67. Dynavax Technologies shares last traded at $15.63, with a volume of 1,836,179 shares.

Analyst Ratings Changes

A number of research firms recently weighed in on DVAX. William Blair lowered shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Wall Street Zen raised Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Dynavax Technologies has an average rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Price Performance

The firm has a fifty day moving average of $12.73 and a two-hundred day moving average of $11.19. The stock has a market capitalization of $1.84 billion, a P/E ratio of -42.24 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. The business had revenue of $94.88 million for the quarter, compared to the consensus estimate of $94.00 million. On average, analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Insider Transactions at Dynavax Technologies

In related news, COO David F. Novack sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $15.49, for a total value of $464,700.00. Following the completion of the transaction, the chief operating officer owned 111,451 shares of the company’s stock, valued at $1,726,375.99. The trade was a 21.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 2.98% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in DVAX. Blair William & Co. IL lifted its stake in shares of Dynavax Technologies by 0.3% during the 2nd quarter. Blair William & Co. IL now owns 2,279,647 shares of the biopharmaceutical company’s stock worth $22,614,000 after purchasing an additional 6,940 shares during the last quarter. Marshall Wace LLP raised its holdings in Dynavax Technologies by 12.2% in the third quarter. Marshall Wace LLP now owns 2,036,003 shares of the biopharmaceutical company’s stock worth $20,218,000 after purchasing an additional 221,069 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Dynavax Technologies by 25.7% during the third quarter. Bank of America Corp DE now owns 1,458,087 shares of the biopharmaceutical company’s stock valued at $14,479,000 after buying an additional 298,106 shares during the last quarter. Glenmede Investment Management LP boosted its holdings in shares of Dynavax Technologies by 23.8% in the 3rd quarter. Glenmede Investment Management LP now owns 1,264,369 shares of the biopharmaceutical company’s stock valued at $12,555,000 after buying an additional 243,240 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Dynavax Technologies by 2.7% in the 3rd quarter. Invesco Ltd. now owns 1,012,954 shares of the biopharmaceutical company’s stock worth $10,059,000 after buying an additional 26,974 shares during the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.